Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience

Author(s): Tiziana Prochilo*, Alessandra Huscher, Federica Andreis, Mara Mirandola, Elisabetta Zaina, Barbara Pomentale, Chiara Pedrali, Laura Zanotti, Stefano Mutti and Alberto Zaniboni

Volume 14, Issue 1, 2019

Page: [66 - 71] Pages: 6

DOI: 10.2174/1574887113666181120111104

Price: $65

Abstract

Background: The most effective agents in the treatment of breast cancer have a common side effect, the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy.

Methods: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean’s scale by patients and operators and a comfort analogic scale by patients. We administered the Hospital Anxiety and Depression Scale questionnaire at the baseline and at the end of treatment to assess the distress related to chemotherapy- induced alopecia.

Results: Among the 46 patients identified, 27 accepted the device. The eligible chemotherapy regimens included docetaxel+cyclophosphamide (TC), doxorubicin+cyclophosphamide (AC) and paclitaxel (P) weekly+trastuzumab (T). 24 pts (89%) completed the treatment; 3 pts (11%) treated with AC prematurely interrupted use of the scalp-cooling device due to inefficacy. After the last cycle of chemotherapy, the number of patient who perceived a HL < grade 2 was 16 (59%). The hair retention reported by operators has been higher (78%). 81.5% of patients well tolerated the treatment.

Conclusion: In our study, the scalp-cooling device reduced chemotherapy-induced alopecia in taxane- based chemotherapy. Furthermore, it suggests a discordance in hair loss perception between patients and operators.

Keywords: Anxiety, breast cancer, chemotherapy, distress, hair loss, scalp cooling.

« Previous Next »
Graphical Abstract

[1]
Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol 2008; 9(8): 730-56.
[2]
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-717.
[3]
Freedman TG. Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs 1994; 17(4): 334-41.
[4]
Browall M, Gaston-Johansson F, Danielson E. Postmenopausal women with breast cancer: Their experiences of the chemotherapy treatment period. Cancer Nurs 2006; 29: 34-42.
[5]
Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. Int J Cancer 2015; 136(5): E442-54.
[6]
Cigler T, Isseroff D, Fiederlein B, et al. Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy. Clin Breast Cancer 2015; 15(5): 332-4.
[7]
Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA 2017; 317(6): 596-605.
[8]
van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51(4): 497-504.
[9]
Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer 2018; 18(1): 19-28.
[10]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[11]
Rugo HS, Serrurier K, Melisko M, et al. Use of the DigniCap™ System to Prevent Hair Loss in Women Receiving Chemotherapy for Stage I Breast Cancer.Presented at: St Gallen 13th International Breast Cancer Conference; March 13-16, 2013; St Gallen, Switzerland
[12]
Benjamin RS. A practical approach to adriamycin toxicology. Cancer Chemother Rep 1975; 6: 191-4.
[13]
Trueb RM. Chemotherapy-induced hair loss. Curr Opin Support Palliat Care 2010; 4(4): 281-4.
[14]
parano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer.N Engl J Med.2008; 358: 1663- 71.
[15]
Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-51.
[16]
Hesketh PJ, Batchelor D, Golant M, et al. Chemotherapy-induced alopecia: Psychosocial impact and therapeutic approaches. Supp Care Canc 2004; 12(8): 543-9.
[17]
Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho-oncol 2014; 23(10): 1103-10.
[18]
Dunnill CJ, Al-Tameemi W, Collett A, et al. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist 2018; 23(1): 84-96.
[19]
van den Hurk CJ, van de Poll-Franse LV, Breed WP, et al. Scalpcoolingto prevent alopecia after chemotherapy can be considered safe in patients with breast cancer. Breast 2013; 22(5): 1001-4.
[20]
Lemieux J, Desbiens C, Hogue JC. Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up. Breast Cancer Res Treat 2011; 128(2): 563-6.
[21]
Young A, Arif A. The use of scalp cooling for chemotherapyinduced hair loss Br J Nurs 2016; 25(10): S22, S24-7
[22]
Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005; 16(3): 352-8.
[23]
Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials. J Eur Acad Dermatol Venereol 2018; 32(5): 720-34.
[24]
Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer Nurs 1988; 11(3): 170-3.
[25]
Macduff C, Mackenzie T, Hutcheon A, et al. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care 2003; 12: 154-61.
[26]
Breed WP, Van den Hurk CJ, Peerbooms M. Presentation, impact and prevention of chemotherapy-induced hair loss: Scalp cooling potentials and limitations. Expert Rev Dermatol 2011; 6: 109-25.
[27]
Friedrichs K, Carstensen MH. Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer - clinical evaluation of sensor-controlled scalp cooling. Springerplus 2014; 3: 500.
[28]
Massey CS. A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 2004; 8(2): 121-30.
[29]
Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017; 317(6): 606-14.
[30]
van den Hurk CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 2012; 20: 3255-60.
[31]
Komen MM, Breed WP, Smorenburg CH, et al. Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel induced alopecia. Support Care Cancer 2016; 24: 2735-41.

Rights & Permissions Print Cite
Article Metrics
69
5
© 2024 Bentham Science Publishers | Privacy Policy